Why is Sun Pharmaceutical Industries Ltd falling/rising?

Recent Price Movement and Market Comparison

Sun Pharma's shares have been on a downward trajectory over the past week, declining by 3.51%, significantly underperforming the Sensex, which remained almost flat with a negligible 0.01% change. Over the last month, the stock has fallen by 6.37%, while the Sensex declined by only 1.31%. Year-to-date, the stock is down 2.94%, slightly worse than the Sensex's 1.94% drop. The one-year performance further highlights the stock's struggles, with a 5.35% loss compared to the Sensex's robust 8.47% gain. Despite this, the longer-term picture remains positive, with the stock delivering a 61.20% return over three years and an impressive 176.36% over five years, outperforming the benchmark indices over these periods.

Technical Indicators and Trading Activity

On the day of the decline, Sun Pharma underperformed its sector by 0.73%, marking the third consecutive day of losses, during which it has shed 3.89%. The stock touched an intraday low of ₹1,659.35, down 2.42%, with a weighted average price indicating that a larger volume of shares traded near this lower price point. This suggests selling pressure at the lower end of the day's range. Furthermore, the stock is trading below all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—signalling a bearish technical outlook. However, investor participation has increased, with delivery volumes rising by 10.52% on 14 Jan compared to the five-day average, indicating heightened trading interest despite the price decline. Liquidity remains adequate, supporting sizeable trades up to ₹7.4 crore based on recent average traded values.

Fundamental Strengths Supporting Long-Term Value

Despite the recent price weakness, Sun Pharmaceutical Industries Ltd maintains strong fundamental credentials. The company boasts a low debt profile, with an average debt-to-equity ratio of zero, underscoring its conservative capital structure. It has demonstrated healthy long-term growth, with net sales increasing at an annual rate of 11.10% and operating profit margins averaging 21.96%. The firm’s return on equity (ROE) stands at an average of 15.21%, reflecting efficient utilisation of shareholders’ funds to generate profits. Operating cash flow for the year is robust at ₹4,198.77 crore, and the company declared a dividend per share of ₹16.00, signalling confidence in its cash generation capabilities. Additionally, cash and cash equivalents are substantial, amounting to ₹122,574.20 crore as of the half-year mark. Institutional investors hold a significant 36.79% stake, indicating strong backing from knowledgeable market participants. Sun Pharma is also among the top 1% of companies rated by MarketsMojo across a universe of 4,000 stocks, further highlighting its quality credentials. With a market capitalisation of ₹4,08,019 crore, it is the largest company in its sector, representing 17.35% of the sector’s market value, and its annual sales constitute nearly 12% of the industry total.

Valuation Challenges and Risks Weighing on the Stock

However, the stock’s premium valuation is a key factor contributing to its recent decline. The company trades at a price-to-book ratio of 5.1, which is expensive relative to its peers’ historical averages. This elevated valuation may be deterring some investors, especially given the stock’s underperformance over the past year. While profits have grown modestly by 3% during this period, the stock has generated a negative return of 5.35%, contrasting sharply with the broader BSE500 index’s 7.89% gain. The price-to-earnings-to-growth (PEG) ratio of 11.5 further suggests that the stock is priced for very high growth expectations, which may be difficult to sustain. These valuation concerns, combined with the stock’s recent technical weakness and relative underperformance, have likely contributed to the selling pressure observed in recent sessions.

Conclusion: Balancing Strong Fundamentals Against Market Sentiment

In summary, Sun Pharmaceutical Industries Ltd’s recent share price decline on 16-Jan reflects a combination of factors. While the company’s long-term fundamentals remain robust, including strong growth, profitability, and a solid balance sheet, the stock is currently facing headwinds from its expensive valuation and underwhelming relative performance over the past year. Technical indicators point to continued short-term weakness, with the stock trading below all major moving averages and experiencing increased selling pressure. Nevertheless, the company’s market leadership, institutional support, and cash strength provide a foundation for potential recovery once valuation concerns ease and market sentiment improves.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →